How to clean mold from your air conditioner safely
It's easy to view an air conditioner as a set-it-and-forget-it appliance, but these workhorse machines require regular cleanings to lower the risk of mold buildup. But if you're like most people, you probably don't know how to clean mold from your air conditioner (or how to identify if it needs cleaning in the first place). With that in mind, here's how to check and clean your unit and how to prevent AC mold in your home in the first place.
There are a few reasons why mold can grow in air conditioners. For starters, "mold is present almost everywhere," Jamie Alan, an associate professor of pharmacology and toxicology at Michigan State University, tells Yahoo Life.
But air conditioners in particular create a mold-friendly environment that allows spores to thrive. "Mold is a common issue in AC units because the cooling process naturally creates moisture," Flores says. "When warm air passes over the evaporator coils, condensation forms."
If the moisture doesn't drain properly from your AC, or if the system stays humid due to poor ventilation or infrequent use, it creates an ideal environment for mold to grow, Flores says.
There are a few things that can happen with a moldy air conditioner. "Mold will reduce efficiency and can also circulate spores throughout the home, which can cause health issues like allergies or respiratory irritation," Flores says.
According to the American Academy of Allergy Asthma & Immunology (AAAAI), mold and mold spores are incredibly common — you're going to breathe some of them in from the air around you. That said, some people are allergic to mold — their immune systems are overly sensitive to specific types of spores, which can lead to more significant reactions from exposure. Common reactions include sneezing, watery eyes, runny nose and nasal congestion. While there are hundreds of types of molds, the AAAAI notes that the most common ones that cause allergic reactions are Alternaria, Aspergillus, Cladosporium and Penicillium.
As to what may happen if mold starts growing inside your AC, Alan says that really depends on the type of mold, as well as how your immune system typically responds to such spores. For instance, people who are immunocompromised or who have underlying respiratory issues are more prone to experience symptoms or health complications from mold exposure.
Additionally, aerosolization of mold is a bigger potential issue than mold growing on a random surface, especially for people who are prone to mold issues, Alan says. If you're chronically exposed to mold by something like your AC blowing spores around, you could develop chronic allergy symptoms or other health concerns. "Patients could have lung infections, which could look like a fever, cough and trouble breathing," Alan says.
Something else to consider: Certain types of molds, like black mold, can release toxins into the air that can make you sick, even if you don't have a mold allergy. "With things like black mold, there are more symptoms that patients may experience like fatigue, mood changes and brain fog," says Alan.
There is also a specific immune reaction to mold spores called hypersensitivity pneumonitis where your lungs become inflamed due to mold exposure. "It leads to a flu-like illness with fever and fatigue, in addition to respiratory symptoms," says Dr. Robert Laumbach, associate professor in the Department of Environmental and Occupational Health and Justice at the Rutgers School of Public Health. "Over time, this could lead to permanent lung damage, so we want to try to catch [it] early."
A key sign that mold in your home may be making you sick is if you find that you're having asthma- or allergy-like symptoms in your home that seem to get better after you leave for the day. "Symptoms usually occur with exposure and then may resolve within hours," says Laumbach. (However, he says that it can take longer for symptoms to clear up for some people, so this isn't always a given.)
Still, all of this doesn't mean you should panic if you happen to find mold in your AC — especially if you otherwise feel fine. "Not every type of mold causes health issues for humans," Alan points out.
There are a few warning signs to look out for. "One of the most noticeable signs is a musty or earthy smell when the system kicks on," Flores says. "It is usually the strongest near vents."
You may even spot mold on the vents or around the evaporator coils and drip pan, Flores says. "Unexplained moisture buildup around the unit or damp, stale air could also be red flags," he adds.
But you may simply be tipped off to the presence of mold in your AC by how you feel when the AC starts running — pay attention for any telltale allergy symptoms mentioned earlier, like sneezing, a runny nose or coughing.
While it's never a bad idea to call in the experts if cleaning your AC seems like an ordeal, in most cases, it's possible to tackle basic cleaning yourself. Flores offers these simple steps.
Flores recommends protecting yourself first. That means wearing gloves, a face mask and goggles. "Disturbing mold can release spores," he says. Failing to protect yourself can increase the likelihood of experiencing allergy symptoms or irritation.
While basic cleaning is fairly straightforward, it's important to familiarize yourself with your unit and to determine whether the company has specific suggestions for ongoing maintenance.
You don't want to be poking around with the electricity still running.
Removing these components allows you to clean in and around them more effectively, identifying any areas where mold may be growing.
"Small amounts of mold in accessible areas like vent covers or drip pans can sometimes be cleaned with a mixture of water and a mild detergent or a diluted bleach solution," Flores says. But as you remove these parts, "be careful not to damage components," he warns. (This is where consulting the owner's manual may come in handy!)
Giving your AC a chance to fully dry before turning it back on will reduce the chances for mold growth to return.
If you suspect that mold is in deeper areas of your air conditioner, like the coils or blower motor, Flores says it's best to use professional-grade equipment and antimicrobials. "That's where trained HVAC pros come in, as we can safely clean and sanitize all affected areas without spreading the mold further," he says.
Getting rid of mold from your AC unit is helpful, but it can come back again if you're not careful. As always, it's best to read the instruction manual for your unit and follow regular maintenance, as recommended. "Proper routine maintenance can address most of these issues before they become a problem for the home," says Sean Goddard, product manager of indoor air quality and coils at HVAC company Trane Technologies.
Beyond that, Goddard says it can be helpful to keep tabs on your indoor humidity. "Indoor humidity should be kept between 30% to 50% for comfort and to prevent mold," he says. "Mold tends to grow when indoor humidity is higher than this range."
If humidity is a big issue in your home, Goddard suggests investing in a dehumidifier to try to help lower those levels.
You may even want to consider using UV light, Goddard says. "UVC light installed over your coil and drain pan can prevent microbial growth and mold," he says.
Laumbach suggests wiping down the inside and outside of your air conditioner regularly to remove dust, and to regularly clean and change your filter. "Dust can be enough food for mold to grow," he says. "You want to keep those coils and the filter clean."
You may even want to consider using an additional air purifier with a HEPA filter, or seeing if your AC unit can use a HEPA filter to tamp down on mold spores circulating in your air, says Tony Abate, a certified mold inspector and vice president and chief technology officer at AtmosAir Solutions. (Check out our favorite air purifiers.)
The Environmental Protection Agency (EPA) also recommends keeping your air conditioning drip pans clean and the drain lines unobstructed and flowing properly.
Mold can be an issue in any air conditioner. Mold exposure can raise the risk of a range of health issues, from allergy symptoms to full-blown infections, making it important to stay on top of the spores in your home. Doing routine air conditioner maintenance and cleanings will help to lower the risk of mold issues happening in the first place.
Omero Flores, CEO of American AC & Heating in Harlingen, Texas
Jamie Alan, RPH, PharmD, PhD, associate professor of pharmacology and toxicology at Michigan State University
Robert Laumbach, MD, MPH, CIH, associate professor in the Department of Environmental and Occupational Health and Justice at the Rutgers School of Public Health
Sean Goddard, product manager of indoor air quality and coils at Trane Technologies
Tony Abate, a certified mold inspector and chief technology officer at AtmosAir Solutions
Our health content is for informational purposes only and is not intended as professional medical advice. Consult a medical professional on questions about your health.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
FDA approves Gamifant® (emapalumab-lzsg) as first-ever treatment for adults and children with Macrophage Activation Syndrome in Still's disease
Approval based on the pooled analysis of our pivotal EMERALD and NI-0501-06 studies, showing 54% of patients treated with Gamifant achieved complete response at week 8. STOCKHOLM, June 28, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that the U.S. Food and Drug Administration (FDA) approved Gamifant® (emapalumab-lzsg) for the treatment of adult and pediatric (newborn and older) patients with hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) in known or suspected Still's disease, including systemic Juvenile Idiopathic Arthritis (sJIA), with an inadequate response or intolerance to glucocorticoids, or with recurrent MAS. "With our expertise in primary hemophagocytic lymphohistiocytosis, we understand the urgency of managing MAS quickly to improve patient outcomes," said Guido Oelkers, Chief Executive Officer at Sobi. "Gamifant is already an established therapy making a meaningful difference for patients with primary HLH, and with this approval, we are excited about the opportunity to positively impact patients affected by MAS in Still's Disease". The approval is based on results of the pooled data from two pivotal studies, the Phase 3 study (NCT05001737) and NI-0501-06 (NCT03311854). 54 percent (21/39) of patients had a complete response at Week 8, and 82% (32/39) achieved clinical MAS remission (VAS ≤1 cm) at Week 8. Safety and tolerability were consistent with previous clinical studies. In patients with HLH/MAS in Still's disease, the most common adverse events (≥20%) were viral infections, including cytomegalovirus infection or reactivation, and rash. "MAS in Still's disease is a serious and potentially life-threatening complication, marked by severe hyperinflammation and, in some cases, multi-organ failure," said Alexei A. Grom, MD, Professor of Pediatrics, Research Director Division of Rheumatology, Cincinnati Children's Hospital Medical Center. "Many patients affected by MAS—both young children and adults—face significant unmet medical needs. With Gamifant now as the first FDA-approved treatment for MAS, we have a new therapeutic option that helps control hyperinflammation and reduce our reliance on high-dose glucocorticoids." MAS, a form of HLH, is a severe complication of rheumatic diseases, occurring most frequently in Still's disease including systemic juvenile idiopathic arthritis and adult-onset Still's disease. HLH/MAS is a rare systemic disorder of interferon gamma (IFNy) driven hyperinflammation with common clinical manifestations such as high persistent fever, elevated ferritin, cytopenias, coagulopathies, and hepatosplenomegaly. Gamifant, an interferon gamma (IFNγ)–blocking antibody, is the first and only FDA approved treatment for adult and pediatric (newborn and older) patients with primary HLH with refractory, recurrent, or progressive disease or intolerance with conventional HLH therapy. U.S. Indication for Gamifant® (emapalumab-lzsg) Please see the full Prescribing Information for Gamifant. About macrophage activation syndrome (MAS) Macrophage activation syndrome (MAS) is a severe complication of rheumatic diseases, most frequently in Still's disease including systemic juvenile idiopathic arthritis (sJIA) – a rare systemic disorder of auto-inflammatory nature with common clinical manifestations such as daily spiking fever, typical transient cutaneous rash, arthritis, lymphadenopathy, hepatosplenomegaly and serositis. MAS is characterized by fever, hepatosplenomegaly, liver dysfunction, cytopenias, coagulation abnormalities and hyperferritinaemia, possibly progressing to multiple organ failure and death. MAS is classified as a secondary form of haemophagocytic lymphohistiocytosis (HLH). About Gamifant® (emapalumab-lzsg) Gamifant® (emapalumab-lzsg) is the only approved anti-interferon gamma (IFNγ) monoclonal antibody. Gamifant works by binding to and neutralizing IFNγ. When IFNγ is secreted in an uncontrolled manner, hyperinflammation occurs within the body. Gamifant is indicated for administration through intravenous infusion over one hour. Gamifant is approved in the US for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. Gamifant is also approved in the US for the treatment of adult and pediatric (newborn and older) patients with hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) in known or suspected Still's disease with an inadequate response or intolerance to glucocorticoids, or with recurrent MAS. About Sobi® Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at and LinkedIn. Contacts For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here. This information is information that Sobi is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, on 28 June 2025 at 00:55 CEST. Gerard TobinHead of Investor Relations This information was brought to you by Cision The following files are available for download: FDA approves Gamifant® (emapalumab-lzsg) as first-ever treatment for adults and children with Macrophage Activation Syndrome in Still’s disease View original content: Sign in to access your portfolio
Yahoo
14 minutes ago
- Yahoo
Is Danaher's M&A Premium Already Priced In?
Danaher Corporation (NYSE: DHR) is a global science and technology innovator focused on designing, manufacturing, and marketing professional, medical, industrial, and commercial products and services. Following the 2023 spin-off of its Environmental & Applied Solutions segment (now Veralto), Danaher has transformed into a pure-play life sciences and diagnostics company, operating through three primary segments: Biotechnology, Life Sciences, and Diagnostics. Warning! GuruFocus has detected 4 Warning Signs with DHR. Biotechnology (~30% of FY2024 revenue) includes Danaher's bioprocessing and genomic reagents businesses, led by brands like Cytiva and Pall, serving pharmaceutical and biotech companies in biologics production and Sciences (~25% of revenue) offers analytical instruments, microscopy, and lab automation tools used by academic institutions, research labs, and clinical diagnostics developers. Key platforms include Leica Microsystems, SCIEX, and Beckman Coulter Life (~45% of revenue) comprises molecular diagnostics, core laboratory diagnostics, and point-of-care testing systems. Notably, Cepheidone of Danaher's flagship brandsoffers rapid molecular diagnostic testing platforms, particularly for infectious diseases like COVID-19, influenza, and tuberculosis. Danaher reported a better-than-feared quarter, beating both top and bottom line estimates significantly and maintaining its annual guidance. In Q1 FY2025, the company's total sales declined by 1% YoY to $5,741 million from $5,796 million in the previous year's quarter. The decline was due to -1.5% impact from foreign exchange translation, which was partially offset by 0.5% growth through acquisitions and flat core revenue growth. The revenue from the Biotechnology segment grew by 6% YoY to $1,612 million, driven by an increase in core sales from high-growth markets due to a rise in demand. The Life Sciences segment saw a decline of 3.5% YoY to $1,680 million due to a decrease in core sales in the genomics consumables business. Revenue from the Diagnostics segment declined by 3% YoY to $2,449 million due to a decline in the sales of the molecular diagnostic business and lower sales in the China region. The adjusted operating profit declined by 50 bps YoY to 29.6% in the quarter due to product mix, administrative cost structure, currency exchange rates, and acquisition Corporation's Growth & Cash Flow Danaher is positioned as a leading provider of life sciences, diagnostic, and biotechnology equipment after spinning off its environmental business (Veralto) in late 2023. Management's guidance for FY2025 assumes relatively stable end-market demand for the rest of the year (similar to Q1 levels). Against this backdrop, I believe Danaher should grow modestly in 2025, reflecting both macro headwinds (tariffs, academic budget cuts) and continued strength in critical segments. I have mentioned the guidance provided by the management below, and my thesis that should help the company achieve it. For fiscal 2025, Danaher reaffirmed core revenue growth of roughly +3% year-over-year. This is consistent with management's view that market demand (globally) will be relatively consistent with Q1, despite tariffs and other pressures. Adjusted diluted EPS guidance was set at $7.60$7.75 (vs. $7.68 consensus). Notably, management raised its Bioprocessing (biotech) growth forecast to the high-single-digits for 2025 (from a prior 67% outlook). Bioprocessing is Danaher's fastest-growing segment. Robust demand for biologic drug development kits and reagents drove higher Q1 results and should continue to drive growth for the remainder of FY2025. Furthermore, the segment is emerging from the destocking cycle, which should help drive sales. In contrast, the Life Sciences segment forecast was trimmed to essentially flat growth, as funding uncertainties slowed academic and government sales (particularly in the U.S.), and China's medical equipment sector has experienced some softness. This should offset the healthy growth in the Bioprocessing segment. However, any rebound in global R&D spending (or continued Chinese stimulus) could surprise on the upside. The Diagnostics segment (especially Cepheid's molecular tests) is expected to see modest growth: Cepheid's respiratory test sales are forecast to reach around $1.7 billion for 2025, but production volume will return to a normal seasonal level after Q1. Overall, Danaher's portfolio remains tilted toward high-growth medical and diagnostics markets, which underpins its steady outlook despite industry headwinds. A key uncertainty is trade policy: Danaher estimates that current U.S. and European tariffs could add roughly $350 million in costs in 2025. However, the company has long worked to offset these costs via its Danaher Business System (DBS), regionalized manufacturing, and pricing strategies. The company should absorb much of the tariff impact through cost actions and supply-chain adjustments (e.g., surcharges or shifting production) rather than curtailing R&D or major initiatives. Because Danaher's products (lab instruments, diagnostics, and biotech consumables) are often mission-critical in healthcare, I believe its end markets will remain resilient even under tariff pressure. In short, tariffs represent a moderate headwind, but Danaher should largely neutralize the impact by expense reductions and operational flexibility. Margins in the upcoming quarters are expected to contract largely due to seasonality in Cepheid's respiratory testing business. Cepheid is one of Danaher's higher?margin units, and Q2 respiratory kit revenue is assumed to be only about $250 million (vs. ~$625 million in Q1). This sharp seasonal drop in high-margin sales, plus normal diagnostic restructuring costs (e.g., the management of China's reimbursement changes), drives the lower quarter?on?quarter profit margin. In sum, I believe the company's margins should continue to decline and improve in the back half of 2025. As a company built on decades of disciplined capital deployment, Danaher's ability to acquire and successfully integrate businesses has been one of its defining competitive advantages. Flagship acquisitions like Cepheid and Pall have meaningfully strengthened Danaher's diagnostics and bioprocessing platforms, but they also introduce inherent integration risks. These include short-term pressures on margins, incremental R&D and SG&A costs, and the complexities of aligning acquired operations with Danaher's operating structure. While such challenges are typical of any acquisitive strategy, Danaher's track record sets it apart. Over the past 30 years, the company has repeatedly demonstrated its ability to extract synergies, improve productivity, and scale acquisitions effectively, largely driven by the Danaher Business System (DBS). This system institutionalizes continuous improvement, cost efficiency, and cultural integration across its portfolio. Though former CEO Larry Culp played a pivotal role in establishing this M&A discipline, the company's current leadership remains strongly committed to DBS principles, which continue to guide its post-acquisition integration efforts. Moreover, Danaher doesn't pursue acquisitions purely for scale; it focuses on high-quality, strategic assets that complement existing platforms and offer long-term value creation. While integration may temporarily weigh on profitability, especially in the form of restructuring expenses, near-term dilution, or elevated investments in innovation, these are often calculated trade-offs for future operating leverage and market expansion. In essence, what might be viewed as a risk is also one of Danaher's greatest strengths; its consistent ability to turn acquired assets into high-margin, growth-focused businesses that reinforce its leadership in life sciences and diagnostics. As of March 31, 2025, investor activity around Danaher reflected a balanced mix of strategic repositioning and continued confidence in the company's long-term potential. Notably, renowned value investors like Joel Greenblatt (Trades, Portfolio) (+29.03%), Wallace Weitz (Trades, Portfolio) (+23.17%), and Arnold Van Den Berg (Trades, Portfolio) (+14.62%) significantly increased their holdings, signaling optimism about Danaher's focused life sciences and diagnostics trajectory. Ken Fisher (Trades, Portfolio) also added modestly to his position (+1.23%), reinforcing steady institutional support. While some investors like Jefferies Group (Trades, Portfolio), Mario Gabelli (Trades, Portfolio), and George Soros (Trades, Portfolio) trimmed their stakes. Danaher is currently trading at a forward P/E of 25.5x and 22.9x on FY2025 and FY2026 estimated EPS of $7.70 and $8.57, respectively, which is below its five-year average forward P/E of 29.9x. On an EV/EBITDA basis, Danaher trades at approximately 18xhigher than peers such as Thermo Fisher Scientific (P/E ~15x, EV/EBITDA ~13x) and Agilent Technologies (P/E ~21x, EV/EBITDA ~15x). While Danaher's valuation premium may appear elevated relative to peers, it reflects the company's consistent execution, higher exposure to recurring revenue from consumables, and strong margin profile. The market seems cautiously optimistic, pricing in steady growth expectations. For FY2025, Danaher's outlook implies stable and controlled expansion, led primarily by strong bioprocessing demand. Although adjusted operating margins are expected to decline in Q2 due to seasonal normalization in the high-margin Cepheid business, a recovery is anticipated in the latter half of the year. Danaher's long-standing execution discipline, anchored by the Danaher Business System (DBS), equips it to offset macro pressures through operational efficiency and agile supply chain management. With a focused portfolio in mission-critical life sciences and diagnostics, Danaher remains well-positioned to deliver modest yet resilient growth in 2025, supported by strategic capital deployment and a strong competitive moat. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
34 minutes ago
- Yahoo
Husband's Attempt at Humor During Ultrasound Backfires. Now He Is ‘Banned' from Speaking in Other Appointments
A husband decided to accompany his wife to her ultrasound appointment The pair were excited to hear their child's heartbeat for the first time However, the wife and doctor were not amused by the husband's joke after hearing the soundExpecting a child is one of life's most emotional and transformative experiences. For one Reddit user and his wife, both 31, the journey to parenthood took an unexpectedly awkward — yet humorous — turn during a routine ultrasound appointment. What began as a joyful, exciting day quickly became a moment of comic misfire that will likely be remembered for years to come. 'We went in for the 12-week scan. Everyone's in a good mood, the tech is sweet, and everything looks great,' the soon-to-be dad writes in the post, setting the stage for what was supposed to be a tender milestone in their pregnancy journey. But then came the moment that often brings tears to parents' eyes: the first sound of the baby's heartbeat. 'She puts the wand over my wife's belly, and the room goes quiet. Then: Lub dub. Lub dub,' he recalls. It was then, caught up in the emotion and the surreal quality of the moment, that the expectant father said what he thought would be a lighthearted comment to break the silence. "Without thinking, I blurt out, 'Sounds like a tiny rave in there,'' he recalls. Unfortunately, his attempt at humor didn't land. 'No one laughs. Not the tech. Not my wife,' he recounts. 'The tech just says flatly, 'It's a heart, not a party.' My wife, God bless her, gives me that 'please stop breathing for a second' look.' The silence that followed was deafening. What was meant to be a bonding moment through shared laughter turned into a lesson in timing — and the unwritten rules of ultrasound etiquette. Recognizing the situation, the dad decided to stay quiet for the rest of the appointment. Although no one found his comment funny at the moment, Reddit users flooded the comments in support of the poster. 'Ehhh they just don't have a sense of humor, that's pretty funny,' one person commented. 'Dad joking it up before you are officially a dad.' The fallout, however, didn't end at the clinic. Later that night, his wife sent him a text from another room. 'Tiny rave. Really?' she asked. The poster noted that he has since been 'permanently banned from speaking during future appointments." While the joke didn't garner any laughs, it did lead to an unofficial nickname for their future son. 'We're naming the baby Oliver,' he writes, 'but I know the real nickname will be DJ Heartbeat.' In the end, this expectant father learned a valuable — and slightly embarrassing — lesson: sometimes, the best thing to say during a poignant moment is nothing at all. Still, it's clear that his heart was in the right place, even if his timing was not. Read the original article on People